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Abstract
Objective:  To  report  a  case  septic  arthritis  with  a  rare  pathogen  in  a  immunosuppressed  child.
Case description:  Male  patient,  6  years  old,  had  liver  transplant  ﬁve  and  half  years  ago  due  to
biliary atresia.  Patient  was  using  tacrolimus  1mg  q.12h.  This  patient  started  to  have  pain  in  left
foot and  ankle  and  had  one  episode  of  fever  3  days  before  hospital  admission.  Physical  exam-
ination showed  weight  17kg,  height  109cm,  temperature  36.4◦C,  with  pain,  swelling  and  heat
in the  left  ankle,  without  other  clinical  signs.  Initial  tests:  hemoglobin  11.7g/dL  hematocrit
36.4%, leukocyte  count  17,600L−1 (7%  banded  neutrophils,  70%  segmented  neutrophils,  2%
eosinophils,  basophils  1%,  13%  lymphocytes,  7%  monocytes)  C-reactive  protein  170.88mg/L.
Joint ultrasound  showed  moderate  effusion  in  the  site.  Patient  was  submitted  to  surgical
procedure  and  Sphingobacterium  multivorum  was  isolated  from  the  effusion.  The  germ  was
susceptible to  broad  spectrum  cephalosporins  (ceftriaxone  and  cefepime)  and  ﬂuoroquinolones
(ciproﬂoxacin  and  levoﬂoxacin),  and  it  was  resistant  to  carbapenemic  antibiotics  and  amino-
glycosides.  He  was  treated  intravenously  with  oxacillin  for  15  days  and  ceftriaxone  for  13  days,
and orally  with  ciproﬂoxacin  for  15  days,  with  good  outcome.
Comments:  The  S.  multivorum  is  a  gram  negative  bacillus  that  belongs  to  Flavobacteriaceae
family and  it  is  considered  non-pathogenic.  It  has  rarely  been  described  as  a  cause  of  infections
in humans,  especially  in  hospital  environment  and  in  immunosuppressed  patients.  This  case
report is  relevant  for  its  unusual  etiology  and  for  the  site  affected,  which  may  be  the  ﬁrst  case
of septic  arthritis  described.
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Artrite  séptica  por  Sphingobacterium  multivorum  em  paciente  pediátrico
imunossuprimido
Resumo
Objetivo:  Relatar  um  caso  de  artrite  séptica  de  etiologia  rara  em  uma  crianc¸a  imunossuprimida.
Descric¸ão do  caso: Paciente  masculino,  seis  anos,  transplantado  hepático  havia  cinco  anos  e
meio devido  à  atresia  de  vias  biliares,  em  uso  de  tacrolimus  1  mg  de  12/12  horas,  iniciou  dor  em
pé e  tornozelo  esquerdo  e  um  episódio  de  febre  três  dias  antes  da  internac¸ão.  Ao  exame  físico,
peso 17  kg,  estatura  109  cm,  temperatura  de  36,4◦C,  com  dor,  edema  e  calor  no  tornozelo
esquerdo e  sem  outras  alterac¸ões.  Exames  da  entrada:  hemoglobina  11,7  g/dL,  hematócrito
36,4%, leucócitos,  17.600/uL  (7%  bastões,  70%  segmentados,  2%  eosinóﬁlos,  1%  basóﬁlo,  13%
linfócitos,  7%  monócitos),  proteína  C  reativa  170,88  mg/L.  Ultrassonograﬁa  articular  evidenciou
moderado derrame  no  recesso  tíbio  talar  anterior  esquerdo.  Feita  limpeza  cirúrgica  com  o
isolamento  do  S.  multivorum  na  cultura  do  líquido  articular,  suscetível  a  um  amplo  espectro
de cefalosporinas  (cefepime  e  ceftriaxone)  e  ﬂuoroquinolonas  (ciproﬂoxacino  e  levoﬂoxacino),
esistente a  carbapenêmicos  e  aminoglicosídeos.  Tratado  com  oxacilina  por  15  dias  e  ceftriaxone
13 dias  intravenoso  e  ciproﬂoxacina  via  oral  por  mais  15  dias  com  boa  evoluc¸ão.
Comentários:  O  Sphingobacterium  multivorum  é  um  bacilo  gram  negativo,  pertencente  à
família Flavobacteriaceae,  considerado  não  patogênico,  tem  sido  raramente  descrito  como
etiologia de  infecc¸ões  em  seres  humanos  principalmente  em  ambientes  hospitalares  e  em
imunossuprimidos.  O  relato  deste  caso  é  relevante  por  sua  etiologia  incomum  e  pelo  sítio
acometido,  pode  ser  este  o  primeiro  caso  de  artrite  séptica  descrito.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este  é  um  artigo
Open Access  sob  a  licença  CC  BY  (https://creativecommons.org/licenses/by/4.0/deed.pt).
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eptic  arthritis  is  caused  by  the  presence  of  a  pathogenic
icroorganism  in  the  joint  space  and  represents  a  diagnos-
ic  and  therapeutic  challenge.  It  affects  mainly  children
nd  Staphylococcus  aureus  is  the  most  common  etiologi-
al  agent.  The  implementation  of  early  and  appropriate
reatment  is  essential  for  a  favorable  evolution  without
equelae.1
Unusual  etiologies  of  septic  arthritis  have  been  reported,
lso  in  immunocompetent  children,  as  in  the  case  described
n  India,  from  which  Achromobacter  xylosoxidans  was
solated,2 but  immunosuppression  is  a  determining  factor
egarding  the  presence  of  other  etiological  agents  rather
han  S.  aureus  and  unfavorable  evolution.
Immunocompromised  patients  are  more  likely  to  develop
nfections  with  unusual  etiologies,  such  as  Mycoplasma
ominis,  which  has  been  associated  with  septic  arthri-
is  in  the  immunosuppressed  pediatric  population.3 In
hese  patients,  the  diagnosis  is  often  delayed,  which  can
etermine  the  evolution  to  erosive  arthritis,  joint  space
estruction  and  sepsis.4
Sphingobacterium  multivorum  is  a  gram-negative,  sapro-
hytic  bacillus  of  the  Flavobacteriaceae  family,  naturally
ound  in  soil,  plants  and  water,5 ﬁrst  described  in  1981.6 It
as  considered  nonpathogenic  for  a  long  time,  but  for  some
ears  now  it  has  been  described  as  a  cause  of  infectious
7rocesses  in  human  beings.
The  objective  of  this  study  is  to  report  the  case  of  an
mmunosuppressed  pediatric  patient  who  developed  septic
rthritis  by  S.  multivorum.
h
b
1ase description
 six  year-old  male  patient  was  admitted  to  the  Pediatric
mergency  Room  with  a history  of  pain  in  the  left  foot  and
nkle,  together  with  difﬁculty  in  ambulation  for  ﬁve  days,
ith  reports  of  an  isolated  fever  peak  (39◦C)  three  days
efore  admission.
At  admission,  his  weight  was  17kg,  height  109cm,  body
ass  index  of  14.3,  heart  rate  of  120bpm,  blood  pressure
f  95×62mmHg,  temperature  of  36.4◦C,  with  swelling  and
armth  in  the  left  ankle  and  mild  pain  at  mobilization.  The
emaining  physical  examination  was  uneventful.
The  patient  was  born  at  39  weeks,  by  cesarean  section.
he  mother  reported  an  uneventful  prenatal  period.  On  the
econd  day  of  life  the  patient  had  jaundice  and  was  submit-
ed  to  phototherapy  for  eight  days.  It  progressed  without
mprovement  and  he  was  referred  for  outpatient  treatment.
t  three  months  of  age,  he  was  diagnosed  with  biliary  atresia
nd  at  six  months  he  was  submitted  to  liver  transplantation.
e  has  received  immunosuppressive  medication  since  then
currently  receiving  tacrolimus,  1mg  q.12hs).  Due  to  the
resence  of  some  phenotypic  deviations  and  single  kidney
n  the  right,  he  is  also  followed  by  the  genetics  discipline  of
he  same  institution,  but  still  without  a  diagnosis.  He  has  a
ormal  karyotype.  He  is  being  followed  at  the  Child  Devel-
pment  Outpatient  Clinic  of  the  same  service  and  all  his
accines  are  up-to-date  for  his  age.Laboratory  tests  at  admission:  hemoglobin  11.7g/dL,
ematocrit  36.4%,  white  blood  cell  count  of  17,600L−1 (7%
and  cells,  70%  segmented,  2%  eosinophils,  1%  basophils,
3%  lymphocytes,  7%  monocytes)  and  C-reactive  protein,
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170.88mg/L.  The  ultrasonography  showed  moderate  joint
effusion  in  the  left  anterior  tibiotalar  recess.
The  patient  was  admitted  and  intravenous  therapy  with
oxacillin  200mg/kg/day  was  started.  Two  days  after  admis-
sion,  the  patient  underwent  surgical  cleaning  of  the  joint
together  with  drainage  of  secretions,  which  were  sent
to  culture  without  other  joint  ﬂuid  analysis.  After  two
days,  the  partial  result  showed  growth  of  gram-negative
bacilli  and  ceftriaxone  (100mg/kg/day)  was  associated  to
oxacillin.
The  joint  ﬂuid  culture  showed  bacterial  growth  on  blood
agar,  in  which  they  appeared  as  non-hemolytic  colonies
of  1mm  in  diameter,  convex,  smooth,  opaque  after  48h-
incubation  at  37◦C.  Bacterial  identiﬁcation  was  carried  out
with  the  Phoenix® automated  system,  which  identiﬁed  Sph-
ingobacterium  multivorum  (90%  certainty),  with  negative
results  for  the  l-glutamic  acid  test.  Additional  tests,  such  as
the  positive  response  to  the  oxidase  and  urease  tests  and
morphological  characteristics  and  sensitivity  proﬁle  con-
ﬁrmed  the  identiﬁcation  of  the  bacterium.
Antimicrobial  susceptibility  was  tested  using  the
Phoenix® automated  system  and  interpreted  with  the  CLSI
document  (M100S25).8 The  isolated  bacteria  were  suscep-
tible  to  a  broad  spectrum  of  cephalosporins  (ceftriaxone
and  cefepime)  and  ﬂuoroquinolones  (ciproﬂoxacin  and
levoﬂoxacin).  Nevertheless,  it  showed  a  resistant  pheno-
type  to  carbapenems  (imipenem  and  meropenem;  minimum
inhibitory  concentration  (MIC)  >8mg/L)  and  aminoglycosides
(Table  1).
Treatment  was  maintained,  as  the  patient  was  in  good
overall  status,  with  no  fever,  no  signs  of  inﬂammation  in
the  joint  and  improvement  in  inﬂammatory  tests  and  white
blood  cell  count.  On  the  13th  day  of  oxacillin  and  11th  day
of  ceftriaxone  use,  he  showed  increased  liver  transaminase
levels  (aspartate  transaminase  (AST)  115U/L  and  alanine
transaminase  (ALT)  114U/L,  respectively)  and  pulse  ther-
apy  was  started  (10mg/kg  methylprednisolone)  for  two  days
with  decrease  in  liver  enzymes  levels  (AST:  43U/L  and  ALT:
79U/L).
He  was  discharged  after  15  days  of  amoxicillin  and  13
days  of  ceftriaxone,  with  maintenance  of  oral  treatment
with  ciproﬂoxacin  for  15  days,  according  to  the  antibiogram.
Table  1  Sensitivity  proﬁle  of  the  isolated  strain  in  the  case
report.
Result Antibiotic  and  MIC
Sensitive  to  Cefepime  (MIC  4),  ceftriaxone  (MIC  4),
levoﬂoxacin  (MIC≤1),
sulfamethoxazole-trimethoprim  (MIC
≤0.5),  ciproﬂoxacin  (MIC  1)
Resistant  to  Tobramycin  (MIC>8),  amikacin  (MIC>32),
gentamicin  (MIC>8),  meropenem  (MIC>8),
piperacillin-tazobactam  (MIC>64),
imipenem  (MIC>8),  aztreonam  (MIC>16),
cefotaxime  (intermediate  resistance  MIC
32)
Central Laboratory of the hospital where the study was carried
out. MIC (minimum inhibitory concentration): in mg/mL.
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t  discharge,  he  showed  no  signs  of  inﬂammation  in  the
ffected  joint  and  CRP  was  2.8mg/L.
He  returned  to  outpatient  care  12  days  after  dis-
harge,  still  receiving  ciproﬂoxacin  250mg  q.12hs.  At  the
ime,  he  was  asymptomatic  and  had  no  complaints.  The
ntibiotic  was  maintained  for  three  more  days.  At  the
ollowing  consultation,  15  days  later,  he  was  clinically
ell  and  a  new  measurement  of  CRP  was  <0.6mg/L,  one
eek  after  the  end  of  treatment.  At  the  monthly  follow-
p,  the  patient  remained  asymptomatic,  with  no  signs  of
nﬂammation  in  the  affected  joint.  He  remains  in  outpa-
ient  treatment,  with  a  follow-up  schedule  for  at  least
ne  year.
iscussion
his  is  a  patient  with  septic  arthritis  caused  by  a  bacterium
hat  rarely  causes  infections  in  humans  and  there  has  been
o  description  of  pyoarthritis  with  this  etiology  to  date.  The
phingobacterium  multivorum  initially  was  not  considered
athogenic,  but  in  recent  years  it  has  been  related  to  infec-
ions,  especially  in-hospital  ones  and  in  immunosuppressed
atients.7
There  has  been  a  description  of  this  agent  not  only  in  hos-
itals  but  also  as  a  contaminant  of  public  transport  objects
n  the  city  of  São  Paulo,  with  resistance  to  cephalexin  and
efazolin.9 The  presence  of  this  bacterium  in  the  envi-
onment  has  already  allowed  its  inoculation  in  a  prostate
iopsy  procedure.10 That  demonstrates  that  S.  multivorum  is
resent  in  the  environment  and  may  be  an  infectious  agent,
ainly  in  immunosuppressed  individuals.
In  1999,  this  bacterium  was  primarily  related  to
pportunistic  infection  in  patients  with  the  human  immu-
odeﬁciency  virus  (HIV)7 and  was  later  described  as  the
riggering  factor  of  sepsis  and  death  in  a  patient  with  this
irus.11 S.  multivorum  has  also  been  associated  to  sep-
is  under  other  circumstances,  such  as  the  duration  of
hemotherapy,12 hemodialysis13 and  in  an  elderly  patient
ith  chronic  obstructive  pulmonary  disease,  hypertension
nd  diabetes14;  and  in  the  airway  colonization  of  patients
ith  cystic  ﬁbrosis,15,16 but  case  reports  of  arthritis  caused
y  this  bacterium  were  not  found  in  the  literature.  The
atient’s  age  range  is  also  noteworthy,  as  most  infection
eports  by  this  microorganism  describes  the  involvement
f  adults  and  elderly  patients  with  comorbidities.8,11--16 In
006,  the  ﬁrst  case  of  sepsis  caused  by  S.  multivorum
as  described  in  Turkey,  in  a  previously  healthy  pediatric
atient,  who  was  treated  with  ampicillin  and  cefotaxime
nd  progressed  with  full  recovery  without  complications.17
 summary  of  the  17  cases  reported  in  the  literature  is  shown
n  Table  2.
Another  point  to  be  emphasized  is  the  importance  of
dequate  antimicrobial  therapy  to  be  implemented  in  such
ases.  The  susceptibility  proﬁle  of  the  strain  described  in
his  case  is  in  accordance  with  a study  by  Lambiase  et  al.,
ith  a  carbapenem  and  aminoglycoside  resistance  proﬁle15;
owever  there  is  an  account  of  respiratory  infection  by
.  multivorum  in  which  a  strain  sensitive  to  Imipenem
as  demonstrated.18 The  present  study  showed  sensi-
ivity  to  third-generation  cephalosporins.  However,  other
eports  showed  resistance  to  these  antibiotics,14,15 including
382  Mendes  MD  et  al.
Table  2  Summary  of  reports  of  infections  caused  by  S.  multivorum.
Author  and  reference  Patient’s  age/site  of
infection/comorbidity
Treatment  Evolution
Areekul11 47  years/sepsis/HIV  and  diabetes Gentamicin  and  ampicillin.
Subsequently,  ceftriaxone  and
sulfamethoxazole-trimethoprim
Death
Freney12 57  years/sepsis/non-Hodgkin’s
lymphoma
Peﬂoxacin  and
sulfamethoxazole-trimethoprim
Full
recovery
Lambiase15 3  positive  samples  in  332  patients
with cystic  ﬁbrosis  and  chronic
pulmonary  infection
No  data  No  data
Aydog˘an17 2  months/sepsis/healthy Ampicillin  and  cefotaxime  full
recovery
Full
recovery
Ramírez18 74  years/pneumonia/chronic
obstructive  pulmonary  disease
Ceftazidime,  cefuroxime.  Full
recovery
Grimaldi5 64  years/septic  shock/obesity  and
coronary  disease
Amoxicillin  and  clavulanate  Full
recovery
Nielsen10 Study  with  3  patients  after  prostate
biopsy.
Patient  1:79  years/cystitis
Patient  2:  59  years/cystitis
Patient  3:  69  years/cystitis
1-  Piperacilina-tazobactam  and
ciproﬂoxacin
2- No  antibiotics
3-  Sulfamethoxazole-trimethoprim
Full
recovery
Potvliege13 43  years/sepsis/on  hemodialysis  Ampicillin  Full
recovery
Reina16 1  year  and  8  months/cystic  ﬁbrosis  Ceftazidime  and  amikacin  Full
recovery
Barahona14 67  years/sepsis/obesity,  arterial
hypertension  and  chronic  obstructive
pulmonary  disease
Cefepime  and  vancomycin,
ciproﬂoxacina
Full
recovery
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R study  that  showed  the  capacity  of  the  bacterium  to
ause  hydrolysis  of  third-generation  cephalosporins  and
arbapenems.19
In  this  case,  both  ciproﬂoxacin  and  sulfamethoxazole-
rimethoprim  could  be  used.  However,  the  choice  of
iproﬂoxacin  for  oral  therapy  after  hospital  discharge  was
ue  to  the  fact  that  the  etiological  agent  had  not  yet  been
escribed  as  the  cause  of  septic  arthritis  in  our  country,
ue  to  its  morphological  similarity  to  Pseudomonas,20 for
hich  this  antibiotic  would  be  a  good  choice,  as  well  as
he  patient’s  immunosuppression.  Studies  have  shown  that
iproﬂoxacin  may  be  used  in  pediatric  patients  according
o  the  analysis  of  risks  and  beneﬁts  in  each  situation.21--23
ne  of  the  indications  by  the  American  Academy  of  Pedi-
trics  and  the  World  Health  Organization  would  be  its  use
n  bacterial  infection  by  gram  negative  microorganisms  in
mmunosuppressed  children.21,24
It  is  noteworthy  the  relevance  of  the  culture  material,
s  it  indicated  the  broader  spectrum  of  the  antimicrobial
herapy,  which  allowed  a  favorable  evolution  of  the  patient’s
ondition.  Early  diagnosis  of  arthritis  also  contributed  to  the
bsence  of  complications  and  sequelae.
Infections  by  S.  multivorum  have  been  studied  more
requently  in  recent  years,  but  studies  in  the  literature
nvolving  this  pathogen  are  still  scarce.  No  articles  were
ound  on  septic  arthritis  related  to  this  bacterium,  which
akes  it  essential  to  report  on  the  case  of  the  studied
atient.unding
his  study  did  not  receive  funding.
onﬂicts of  interest
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